Skip to main content
Erschienen in: Indian Journal of Surgery 4/2017

03.09.2016 | Original Article

Major Liver Resection for Large and Locally Advanced Hepatocellular Carcinoma

verfasst von: Viniyendra Pamecha, Shridhar Vasantrao Sasturkar, Piyush Kumar Sinha, Shyam Sundar Mahansaria, Kishore G. S. Bharathy, Senthil Kumar, Archana Rastogi

Erschienen in: Indian Journal of Surgery | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Optimal management of large and locally advanced hepatocellular carcinoma (HCC) remains a clinical challenge especially in patients with chronic liver disease (CLD). We present our experience of major liver resection for large and locally advanced HCC. Prospectively collected data of patients with large and locally advanced HCC who underwent major liver resection between March 2011 and May 2015. The outcome measures of interest were the characteristics of tumor, surgical outcome, and overall as well as disease-free survival. Eighteen patients (14 male) with median age of 59 years (20 to 73 years) with good performance status underwent resection. Fifteen patients were in Child Pugh class A and three in class B. On contrast-enhanced computed tomography (CECT) scan, four patients had lobar/segmental portal vein involvement, two patients had bilobar disease, and one had biliary obstruction. Seven patients underwent extended resection (>5 segments), five right hepatectomy, two modified right hepatectomy, one modified right hepatectomy with wedge resection of segment six, two left hepatectomy, and one left lateral sectionectomy. On histopathology, 12 were solitary and six were multiple, the median tumor diameter was 9 cm (5–18 cm). All 18 patients had R0 resection. Eight patients had cirrhosis, six had fibrosis, and four had chronic hepatitis. Vascular invasion was noticed in 12 and out of these, six had large-vessel embolization. Morbidity according to Clavien-Dindo class was grades 1–11, grades 2–5, grade 3B-1, and grades 5–1. After a median follow-up of 32 months (6–54 months), the overall survival at 1 and 3 years was 83 and 54 %, respectively. The disease-free survival at 1 and 3 years was 75 and 54 % respectively. In carefully selected patients with large and locally advanced HCC, acceptable perioperative and medium term outcomes can be achieved with major liver resection.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed
3.
Zurück zum Zitat Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRefPubMed Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRefPubMed
4.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver. J Hepatol 35:421–430CrossRefPubMed Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver. J Hepatol 35:421–430CrossRefPubMed
5.
Zurück zum Zitat Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, et al. (2008) The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for Hepatocellular carcinoma—survival analysis of 3892 patients. Eur J Cancer 44:1000–1006CrossRefPubMed Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, et al. (2008) The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for Hepatocellular carcinoma—survival analysis of 3892 patients. Eur J Cancer 44:1000–1006CrossRefPubMed
7.
Zurück zum Zitat Pascual S, Zapater P, Such J, García-Herola A, Sempere L, Irurzun J, et al. (2006) Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 26:673–679CrossRefPubMed Pascual S, Zapater P, Such J, García-Herola A, Sempere L, Irurzun J, et al. (2006) Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int 26:673–679CrossRefPubMed
8.
Zurück zum Zitat Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. (2006) Prospective validation of the Barcelona clinic liver cancer staging system. J Hepatol 44:723–731CrossRefPubMed Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. (2006) Prospective validation of the Barcelona clinic liver cancer staging system. J Hepatol 44:723–731CrossRefPubMed
9.
Zurück zum Zitat Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41:707–716CrossRefPubMed Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41:707–716CrossRefPubMed
10.
Zurück zum Zitat Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, et al. (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12:364–373CrossRefPubMed Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, et al. (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12:364–373CrossRefPubMed
11.
Zurück zum Zitat Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagorney DM, et al. (2005) Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 140:450–457CrossRefPubMed Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagorney DM, et al. (2005) Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 140:450–457CrossRefPubMed
12.
Zurück zum Zitat Chirica M, Scatton O, Massault PP, Aloia T, Randone B, Dousset B, et al. (2008) Treatment of stage IVA hepatocellular carcinoma. Should we reappraise the role of surgery? Arch Surg 143:538–543CrossRefPubMed Chirica M, Scatton O, Massault PP, Aloia T, Randone B, Dousset B, et al. (2008) Treatment of stage IVA hepatocellular carcinoma. Should we reappraise the role of surgery? Arch Surg 143:538–543CrossRefPubMed
13.
Zurück zum Zitat Torzilli G, Donadon M, Marconi M, Palmisano A, Del Fabbro D, Spinelli A, et al. (2008) Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona clinic liver cancer classification: results of a prospective analysis. Arch Surg 143:1082–1090CrossRefPubMed Torzilli G, Donadon M, Marconi M, Palmisano A, Del Fabbro D, Spinelli A, et al. (2008) Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona clinic liver cancer classification: results of a prospective analysis. Arch Surg 143:1082–1090CrossRefPubMed
14.
Zurück zum Zitat Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134:1908–1916CrossRefPubMed Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134:1908–1916CrossRefPubMed
15.
Zurück zum Zitat Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. (2013) A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group. Ann Surg 257:929–937CrossRefPubMed Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. (2013) A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group. Ann Surg 257:929–937CrossRefPubMed
16.
Zurück zum Zitat Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 cases of hepatocellular carcinoma at a western center. Ann Surg 229(6):790–799 discussion 799-800CrossRefPubMedPubMedCentral Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 cases of hepatocellular carcinoma at a western center. Ann Surg 229(6):790–799 discussion 799-800CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMed Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655CrossRefPubMed
18.
Zurück zum Zitat Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503CrossRefPubMed Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503CrossRefPubMed
19.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Choi SB, Kim HJ, Song TJ, Ahn HS, Choi SY (2014) Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatobiliary Pancreat Sci 21:639–647CrossRefPubMed Choi SB, Kim HJ, Song TJ, Ahn HS, Choi SY (2014) Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatobiliary Pancreat Sci 21:639–647CrossRefPubMed
21.
Zurück zum Zitat Tang YH, Zhu WJ, Wen TF (2014) Influence of clinically significant portal hypertension on hepatectomy for hepatocellular carcinoma: a meta-analysis. Asian Pac J Cancer Prev 15(4):1649–1654CrossRefPubMed Tang YH, Zhu WJ, Wen TF (2014) Influence of clinically significant portal hypertension on hepatectomy for hepatocellular carcinoma: a meta-analysis. Asian Pac J Cancer Prev 15(4):1649–1654CrossRefPubMed
22.
Zurück zum Zitat Poon RTP, Fan ST, Wong J (2002) Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 194:592–602CrossRefPubMed Poon RTP, Fan ST, Wong J (2002) Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 194:592–602CrossRefPubMed
23.
Zurück zum Zitat Yeh CN, Lee WC, Chen MF (2003) Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang gung memorial hospital. Ann Surg Oncol 10:1070–1076CrossRefPubMed Yeh CN, Lee WC, Chen MF (2003) Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang gung memorial hospital. Ann Surg Oncol 10:1070–1076CrossRefPubMed
24.
Zurück zum Zitat Shrager B, Jibara GA, Tabrizian P, Schwartz ME, Labow DM, Hiotis S (2013) Resection of large hepatocellular carcinoma (>10 cm): a unique western perspective. J Surg Oncol 107:111–117CrossRefPubMed Shrager B, Jibara GA, Tabrizian P, Schwartz ME, Labow DM, Hiotis S (2013) Resection of large hepatocellular carcinoma (>10 cm): a unique western perspective. J Surg Oncol 107:111–117CrossRefPubMed
25.
Zurück zum Zitat Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F (2009) Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 249:118–123CrossRefPubMed Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F (2009) Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 249:118–123CrossRefPubMed
26.
Zurück zum Zitat Lee SG, Hwang S, Jung JP, Lee YJ, Kim KH, Ahn CS (2007) Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions. Br J Surg 94:320–326CrossRefPubMed Lee SG, Hwang S, Jung JP, Lee YJ, Kim KH, Ahn CS (2007) Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions. Br J Surg 94:320–326CrossRefPubMed
27.
Zurück zum Zitat Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC (2007) Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol 14:2817–2823CrossRefPubMed Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC (2007) Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol 14:2817–2823CrossRefPubMed
28.
Zurück zum Zitat Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. (2006) Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 243(2):229–235CrossRefPubMedPubMedCentral Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. (2006) Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 243(2):229–235CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P'eng FK (2005) Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br J Surg 92:348–355CrossRefPubMed Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P'eng FK (2005) Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br J Surg 92:348–355CrossRefPubMed
31.
Zurück zum Zitat Sharr WW, Chan SC, CM L (2014) Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation 97(Suppl 8):S10–S17CrossRefPubMed Sharr WW, Chan SC, CM L (2014) Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation 97(Suppl 8):S10–S17CrossRefPubMed
32.
Zurück zum Zitat Parikh ND, Waljee AK, Singal AG (2015) Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 21(9):1142–1152CrossRefPubMed Parikh ND, Waljee AK, Singal AG (2015) Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 21(9):1142–1152CrossRefPubMed
33.
Zurück zum Zitat Bhangui P, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS, et al. (2016) Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg 264(1):155–163CrossRefPubMed Bhangui P, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS, et al. (2016) Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg 264(1):155–163CrossRefPubMed
34.
Zurück zum Zitat Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, et al. (2015) The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62(2):440–451CrossRefPubMed Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, et al. (2015) The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62(2):440–451CrossRefPubMed
Metadaten
Titel
Major Liver Resection for Large and Locally Advanced Hepatocellular Carcinoma
verfasst von
Viniyendra Pamecha
Shridhar Vasantrao Sasturkar
Piyush Kumar Sinha
Shyam Sundar Mahansaria
Kishore G. S. Bharathy
Senthil Kumar
Archana Rastogi
Publikationsdatum
03.09.2016
Verlag
Springer India
Erschienen in
Indian Journal of Surgery / Ausgabe 4/2017
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI
https://doi.org/10.1007/s12262-016-1545-3

Weitere Artikel der Ausgabe 4/2017

Indian Journal of Surgery 4/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.